Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heme arginate: effects on hemostasis.

L Volin1, V Rasi, E Vahtera

  • 1Third Department of Medicine, University of Helsinki, Finland.

Blood
|March 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).

Bone marrow transplantation·2019
Same author

Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis.

Journal of internal medicine·2018
Same author

Genomic prediction of relapse in recipients of allogeneic haematopoietic stem cell transplantation.

Leukemia·2018
Same author

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.

Journal of internal medicine·2017
Same author

What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?

Journal of internal medicine·2017
Same author

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.

Bone marrow transplantation·2017
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Heme arginate, a new treatment for acute porphyric attacks, shows minimal impact on hemostasis. Unlike hematin, it is more stable, suggesting a safer profile for treating heme deficiency disorders.

Area of Science:

  • Biochemistry
  • Hematology
  • Pharmacology

Background:

  • Hematin is used for acute porphyric attacks but can cause hemostasis disturbances due to degradation products.
  • Heme arginate is a novel heme compound developed for porphyria treatment, showing good tolerability in preliminary studies.

Purpose of the Study:

  • To evaluate the effects of heme arginate infusion on hemostasis parameters in healthy volunteers.
  • To compare the stability and degradation rates of heme arginate versus hematin.

Main Methods:

  • Seven healthy volunteers received a heme arginate infusion.
  • Coagulation and fibrinolysis parameters were monitored.
  • Degradation rates of heme arginate and hematin were compared in vitro.

Related Experiment Videos

Main Results:

  • Most hemostasis parameters remained unchanged after heme arginate infusion.
  • A transient, insignificant decrease in coagulation factor X was observed.
  • Heme arginate demonstrated significantly higher stability with only 1% degradation in 4 hours compared to 61% for hematin.

Conclusions:

  • Heme arginate appears to have a favorable hemostasis profile, likely due to its superior stability.
  • The findings support the use of heme arginate for acute porphyrias and other heme deficiency conditions.